AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15327617
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 400 microg every 3 hours for a maximum of five doses
Trial: 9581985
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (150 mg caffeine)
Trial: 11509481
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (<2 mg caffeine)
Trial: 17456569
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 0.67 mg/d
Trial: 14735126
Drug: Trihexyphenidyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trihexyphenidyl (1 mg)
Trial: 14735126
Drug: Trihexyphenidyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trihexyphenidyl (2 mg)
Trial: 28583162
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 mg/kg daily for 3 weeks)
Trial: 26496361
Drug: Facilitated tucking
RxNorm normalized name: Tucks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated tucking with oral glucose
Trial: 26496361
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water (placebo)
Trial: 26496361
Drug: Facilitated tucking
RxNorm normalized name: Tucks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated tucking with oral water
Trial: 23369426
Drug: Both written
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both written and oral information modalities
Trial: 23369426
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information modality (presentation)
Trial: 15292331
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg twice a day)
Trial: 9657323
Drug: Mycobacterium vaccae
RxNorm normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium vaccae immunotherapy
Trial: 30427093
Drug: Oral nanocurcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nanocurcumin (120 mg/day)
Trial: 16704555
Drug: Glipizide 2.5
RxNorm normalized name: glipizide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide 2.5 mg once daily for 6 months
Trial: 30793431
Drug: Elobixibat 10
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 10 mg/d
Trial: 30793431
Drug: Elobixibat 15
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 15 mg/d
Trial: 30793431
Drug: Elobixibat (varied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elobixibat (varied doses 5-15 mg/d)
Trial: 28270028
Drug: Health Education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Education Session (HES) administered to the Intervention Group (IG)
Trial: 21846617
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once daily in addition to standard treatment
Trial: 2566942
Drug: Glucose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (100 g p.o. 45 min before GHRH)
Trial: 50159
Drug: Delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-9-tetrahydrocannabinol (THC) 20 mg
Trial: 50159
Drug: Delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delta-9-tetrahydrocannabinol (THC) 10 mg
Trial: 29934985
Drug: Medial knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial knee pain (MP) induced by hypertonic saline (0.5 mL) injection
Trial: 29934985
Drug: Lateral knee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral knee pain (LP) induced by hypertonic saline injection
Trial: 28669654
Drug: 3% H2
RxNorm normalized name: Hydrogen Peroxide 3%
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% H2 gas inhalation (1 hour twice a day for 2 weeks)
Trial: 28669654
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous medications (for the initial 7 days)
Trial: 9638964
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg
Trial: 23197250
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg plus Ezetimibe 10 mg
Trial: 21645439
Drug: UDCA-monotherapy
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA-monotherapy
Trial: 18075220
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of plant sterol in 15 g dressing for 4 weeks
Trial: 18075220
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day of plant sterol in 15 g dressing for 4 weeks
Trial: 18075220
Drug: 1200 mg/day
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/day of plant sterol in 15 g dressing for 4 weeks
Trial: 18075220
Drug: 2400 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/day of plant sterol in 45 g dressing for 4 weeks
Trial: 10734658
Drug: No ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No ATRA administration
Trial: 9182474
Drug: Mefloquine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (250 mg per week, preceded by a loading dose of 250 mg/d for 3 days)
Trial: 9182474
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg per day)
Trial: 9182474
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for both drugs
Trial: 2957520
Drug: Functional restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional restoration treatment program
Trial: 2957520
Drug: Small treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small treatment dropout group
Trial: 22961573
Drug: RM-131 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RM-131 (100 μg s.c.)
Trial: 19544672
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium carbonate (CAL, 1.2 to 1.8 g/day)
Trial: 8236070
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (500 micrograms twice a day)
Trial: 3912618
Drug: T-CAF (Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-CAF (Chemotherapy plus Tamoxifen)
Trial: 3912618
Drug: CAF (Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (Chemotherapy only)
Trial: 26253006
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CD34+ stem cells (10 to 15 × 10^6 cells/kg)
Trial: 26253006
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CD34+ stem cells (4 to 6 × 10^6 cells/kg)
Trial: 15726101
Drug: High-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroid therapy (> or =25 mg prednisolone or > or =4 mg dexamethasone daily for > or =4 weeks)
Trial: 10588995
Drug: Zafirlukast 80
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast 80 mg twice daily
Trial: 656284
Drug: Intra-articular prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular prednisolone acetate (50 mg and 100 mg)
Trial: 28705153
Drug: TDF/FTC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC tablet once daily (Perfect adherence)
Trial: 24683783
Drug: Buccal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buccal midazolam spray
Trial: 21076361
Drug: Low-dose methadone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methadone (0.1 mg/kg/dose)
Trial: 21076361
Drug: High-dose methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methadone (based on weight and fentanyl infusion rate)
Trial: 19801052
Drug: Once-daily physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily physiotherapy (Control)
Trial: 11264335
Drug: Moclobemide plus
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide plus interpersonal therapy (IPT)
Trial: 9272198
Drug: Pirlindole (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirlindole (150-300 mg daily)
Trial: 7593728
Drug: Moclobemide (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300-600 mg daily)
Trial: 8100105
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) 0.5 mg subcutaneously
Trial: 3555057
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for five days
Trial: 1538580
Drug: Taurine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (3 g/day)
Trial: 20025642
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin for 21 days
Trial: 12633920
Drug: Corticosteroid (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (prednisolone 2 mg/kg per day)
Trial: 12633920
Drug: Antihistamine (chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (chlorpheniramine maleate 0.35 mg/kg per day)
Trial: 30714880
Drug: Standard buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard buprenorphine treatment
Trial: 26355615
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2% and benzoyl peroxide 3.75% aqueous gel
Trial: 31713863
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (limited duration anticoagulation)
Trial: 28216012
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (received HMME-PDT treatment in the second session)
Trial: 22015710
Drug: DE plus
RxNorm normalized name: Nicotinamide Plus Zinc Plus Folic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DE plus metformin
Trial: 19808138
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of levofloxacin 500 mg
Trial: 16639920
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA): 3 mg dissolved in 250 mg of physiological saline given every 12 hours for a maximum of 20 days.
Trial: 16639920
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of rt-PA used for treatment of myocardial infarction (not specified in the abstract).
Trial: 16277666
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs
Trial: 2216299
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDA) 45 mg/m2 orally on 3 consecutive days every 28 days
Trial: 2216299
Drug: Doxorubicin (ADRIA)
RxNorm normalized name: doxorubicin Injection [Adriamycin]
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (ADRIA) 75 (60) mg/m2 intravenously every 21 days
Trial: 358756
Drug: Diazepam (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (intramuscular injections)
Trial: 358756
Drug: Barbital (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbital (oral route)
Trial: 26019183
Drug: Low-dose THC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose THC (2.9%) with alcohol
Trial: 26019183
Drug: High-dose THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose THC (6.7%) with alcohol
Trial: 23530566
Drug: Thai traditional
RxNorm normalized name: Thai galangal extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thai traditional massage (2-hour session, twice a week for 4 weeks)
Trial: 19159408
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg daily) for 10 days
Trial: 10441849
Drug: haemocorrecting drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haemocorrecting drugs (rheopolyglucin, euphyllin, aspirin, curantyl, trental)
Trial: 10441849
Drug: vasoactive and
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vasoactive and metabolic drugs (cavinton, complamin, actovegin)
Trial: 7790793
Drug: High‐dose, motorized,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose, motorized, continuous traction (35%-50% of total body weight)
Trial: 7790793
Drug: Sham or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham or low‐dose traction (0-20% of body weight)
Trial: 7790793
Drug: High‐dose, motorized,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose, motorized, continuous traction
Trial: 7790793
Drug: Sham or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham or low‐dose traction
Trial: 23973639
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg/day (Group B)
Trial: 20558925
Drug: Culture-guided triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture-guided triple therapy
Trial: 15888211
Drug: Naloxone (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.04 mg/kg, I.V.)
Trial: 1971027
Drug: Terazosin (2-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (2-40 mg, once daily)
Trial: 7060823
Drug: Sodium meclofenamate
RxNorm normalized name: Meclofenamate Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium meclofenamate (300 mg daily)
Trial: 17453399
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg daily)
Trial: 31266654
Drug: Dapagliflozin 5-mg/saxagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP
Trial: 31266654
Drug: Dapagliflozin 10-mg/saxagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10-mg/saxagliptin 5-mg/metformin 1000-mg XR FCDP
Trial: 24584741
Drug: 20% intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% intralipid infusion
Trial: 7531852
Drug: Hydromorphone (1‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (1‐6 mg/70 kg)
Trial: 26948856
Drug: 16 mg/day
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/day BUP (BUP16)
Trial: 25110280
Drug: Canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 300 mg (Treatment C)
Trial: 19675104
Drug: P +
RxNorm normalized name: Stress Formula B-Comp + Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P + 60 mg/d iron (Fe)
Trial: 15240537
Drug: Conventional-dose anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose anthracycline-based chemotherapy
Trial: 15240537
Drug: High-dose anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anthracycline-based plus alkylating chemotherapy
Trial: 15240537
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (surgical or chemotherapy regimen and histological type)
Trial: 9054819
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy administered within 2 hours of symptom onset
Trial: 9054819
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy administered after 4 to 6 hours of symptom onset
Trial: 9054819
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy administered after 1 hour of arrival at hospital
Trial: 3322848
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac 75 mg
Trial: 2427301
Drug: middle-molecular hydroxyethyl
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: middle-molecular hydroxyethyl starch solution
Trial: 2427301
Drug: isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic sodium chloride solution
Trial: 7564132
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (Doxium) 3 x 500 mg orally for 2 years
Trial: 2201161
Drug: 1% sodium
RxNorm normalized name: Dextrose 5% and 0.11% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sodium hyaluronate solution
Trial: 2201161
Drug: 2% methylcellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% methylcellulose solution (placebo)
Trial: 7299760
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg 3 days/week)
Trial: 7299760
Drug: D-penicillamine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (250 mg increments at 2-3 monthly intervals)
Trial: 23807094
Drug: CRP concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP concentration ≥ 40 mg/L
Trial: 21155632
Drug: MPH ER
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH ER (up to 1 mg/kg per day)
Trial: 19951567
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily insulin lispro low mix 25
Trial: 19951567
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin mix 30/70
Trial: 19951567
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro low mix 25
Trial: 7679583
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg three times a day after a 6.25 mg test dose, n = 32)
Trial: 30593463
Drug: Salbutamol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (4 mg, three times a day)
Trial: 28791362
Drug: COPD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD treatment group
Trial: 26401255
Drug: HIV protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV protease inhibitors (HIV‐PIs) saquinavir and ritonavir (SQV+RIT)
Trial: 23467813
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid plus vitamin B12 supplementation (2 mg of folic acid and 400 μg of vitamin B12 daily for 16 weeks)
Trial: 17079524
Drug: Counterstrain treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counterstrain treatment
Trial: 9564119
Drug: Chlorpromazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (25 mg/day) + Tropisetron (TRO) (5 mg/day)
Trial: 9564119
Drug: Chlorpromazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (25 mg/day) + Tropisetron (5 mg/day) + Dexamethasone (2 mg/day)
Trial: 9564119
Drug: Tropisetron (TRO)
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (TRO) (5 mg/day)
Trial: 2721537
Drug: Co-dergocrine 4
RxNorm normalized name: co-dergocrine mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-dergocrine 4 mg/day for 3 weeks
Trial: 5483323
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate administered with tetracycline
Trial: 5483323
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate administered with oxytetracycline
Trial: 5483323
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate administered with methacycline